These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17107351)

  • 1. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
    Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI
    Br J Haematol; 2006 Dec; 135(5):688-92. PubMed ID: 17107351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Measurement and clinical significance of serum DKK-1 and sRANKL levels in multiple myeloma].
    Bao L; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2011 Mar; 50(3):243-7. PubMed ID: 21600091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
    Terpos E; Fragiadaki K; Konsta M; Bratengeier C; Papatheodorou A; Sfikakis PP
    Clin Exp Rheumatol; 2011; 29(6):921-5. PubMed ID: 22032557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of bortezomib combined with bisphosphonates on bone metabolism index in multiple myeloma].
    Qu S; Liao LS; Wei TN; Lin Y; Chen BY; Chen WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1482-5. PubMed ID: 24370033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab].
    Tatekoshi A; Sato T; Ibata S; Hashimoto A; Kamihara Y; Horiguchi H; Ono K; Takada K; Iyama S; Takimoto R; Kobune M; Kato J
    Rinsho Ketsueki; 2014 Nov; 55(11):2271-6. PubMed ID: 25501406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
    Terpos E; Christoulas D; Kastritis E; Katodritou E; Papatheodorou A; Pouli A; Kyrtsonis MC; Michalis E; Papanikolaou X; Gkotzamanidou M; Koulieris E; Gavriatopoulou M; Zervas K; Dimopoulos MA;
    Am J Hematol; 2014 Jan; 89(1):34-40. PubMed ID: 23983166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
    Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
    Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
    Shiota J; Izumi N; Kasahara H; Tagawa H; Chiba T; Nihei H
    Nihon Jinzo Gakkai Shi; 2010; 52(8):1022-8. PubMed ID: 21254698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to bortezomib and activation of osteoblasts in multiple myeloma.
    Zangari M; Yaccoby S; Cavallo F; Esseltine D; Tricot G
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):109-14. PubMed ID: 17026821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
    Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
    Terpos E; Christoulas D; Katodritou E; Bratengeier C; Gkotzamanidou M; Michalis E; Delimpasi S; Pouli A; Meletis J; Kastritis E; Zervas K; Dimopoulos MA
    Int J Cancer; 2012 Sep; 131(6):1466-71. PubMed ID: 22052418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
    Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of different regimens on bone disease of multiple myeloma].
    Bao L; Lu XJ; Zhang XH; Lai YY; Zhu HH; Lu J; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):221-5. PubMed ID: 21569702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis.
    Ambroszkiewicz J; Sands D; Gajewska J; Chelchowska M; Laskowska-Klita T
    Adv Med Sci; 2013; 58(2):338-43. PubMed ID: 24277958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.